Artur Oręziak
A5009516713- Cardiac pacing and defibrillation studies
- Cardiomyopathy and Myosin Studies
- Cardiac Arrhythmias and Treatments
- Cardiovascular Function and Risk Factors
- Cardiac electrophysiology and arrhythmias
- ECG Monitoring and Analysis
- Cardiac Structural Anomalies and Repair
- Cardiovascular Effects of Exercise
- Congenital Heart Disease Studies
- Heart Failure Treatment and Management
- Heart Rate Variability and Autonomic Control
- Atrial Fibrillation Management and Outcomes
- Cardiac Valve Diseases and Treatments
- Neurological disorders and treatments
- Cardiovascular Syncope and Autonomic Disorders
- Viral Infections and Immunology Research
- Cardiovascular and exercise physiology
- History of Medicine Studies
- Cardiovascular Health and Disease Prevention
- Advanced battery technologies research
- Cardiac Health and Mental Health
- Stroke Rehabilitation and Recovery
- Cardiac Imaging and Diagnostics
- Cardiac tumors and thrombi
- Infective Endocarditis Diagnosis and Management
Institute of Cardiology
2015-2025
Cardinal Stefan Wyszyński University in Warsaw
2019-2025
Sequoia (United States)
2024
SEQUOIA (Italy)
2024
Brigham and Women's Hospital
2024
Lahey Medical Center
2024
Baim Institute for Clinical Research
2024
Harvard University
2024
Oregon Health & Science University
2024
Lahey Hospital and Medical Center
2024
Guidelines recommend exercise training as a component of heart failure management. There are large disparities in access to rehabilitation, and introducing hybrid comprehensive telerehabilitation (HCTR) consisting remote monitoring at patients' homes might be an appealing alternative.To assess whether potential improvements quality-of-life outcomes after 9-week HCTR intervention patients with translate into improvement clinical during extended 12 24 months follow-up, compared usual care.The...
BackgroundOne of the major determinants exercise intolerance and limiting symptoms among patients with obstructive hypertrophic cardiomyopathy (HCM) is an elevated intracardiac pressure resulting from left ventricular outflow tract obstruction. Aficamten oral selective cardiac myosin inhibitor that reduces gradients by mitigating hypercontractility.MethodsIn this phase 3, double-blind trial, we randomly assigned adults symptomatic HCM to receive aficamten (starting dose, 5 mg; maximum 20 mg)...
Data assessing the long-term safety and efficacy of mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy are needed. The authors sought to evaluate interim results from EXPLORER-Long Term Extension (LTE) cohort MAVA-LTE (A Long-Term Safety Study Mavacamten in Adults Who Have Completed EXPLORER-HCM; NCT03723655). After or placebo withdrawal at end parent EXPLORER-HCM (Clinical Evaluate [MYK-461] With Symptomatic Obstructive Hypertrophic Cardiomyopathy; NCT03470545),...
Long-term safety and efficacy of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) are unknown. MAVA-LTE (NCT03723655) is an ongoing, 5-year, open-label extension study designed to evaluate the long-term effects mavacamten.
Mavacamten, a cardiac myosin inhibitor, improved peak oxygen uptake (pVO2) in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) the EXPLORER-HCM study. However, full extent of mavacamten's effects on exercise performance remains unclear.To investigate effect mavacamten physiology using cardiopulmonary testing (CPET).Exploratory analyses data from study, randomized, double-blind, placebo-controlled, phase 3 trial that was conducted 68 cardiovascular centers 13 countries....
Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by left ventricular (LV) hypertrophy, LV outflow tract obstruction, and atrial dilation, which can be associated with progressive heart failure, fibrillation, stroke. Aficamten a next-in-class cardiac myosin inhibitor that reduces obstruction modulating contractility, the potential to reverse pathological remodeling and, in turn, reduce cardiovascular events. This study sought investigate effect of aficamten on compared placebo...
The aim of this study was to report safety and efficacy aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM) over 36 weeks the ongoing FOREST-HCM trial.
Background Aficamten, a novel cardiac myosin inhibitor, reversibly reduces hypercontractility in obstructive hypertrophic cardiomyopathy. We present prespecified analysis of the pharmacokinetics, pharmacodynamics, and safety aficamten SEQUOIA‐HCM (Safety, Efficacy, Quantitative Understanding Obstruction Impact Aficamten HCM). Methods Results A total 282 patients with cardiomyopathy were randomized 1:1 to daily (5–20 mg) or placebo between February 1, 2022, May 15, 2023. dosing targeted...
Standard-of-care (SoC) medications for the treatment of obstructive hypertrophic cardiomyopathy (oHCM) are recommended as first-line therapy despite lack evidence from controlled clinical trials and well known off-target side effects.
Disopyramide, used in obstructive hypertrophic cardiomyopathy (oHCM) for its negative inotropic properties mediated by reduction cytosolic calcium, has been recommended decades as an option to relieve resistant obstruction. Aficamten is a selective cardiac myosin inhibitor that reduces hypercontractility directly reducing myosin-actin interaction. This study aims investigate the safety and efficacy of concomitant use withdrawal disopyramide patients with symptomatic oHCM receiving aficamten....
Abstract Background and Aims Patients with obstructive hypertrophic cardiomyopathy (oHCM) treated aficamten in SEQUOIA-HCM (NCT05186818) demonstrated marked improvement symptoms functional capacity. This analysis explores whether oHCM mild experience similar clinical benefit as patients more advanced limitation. Methods (N=282) were grouped at baseline according to symptom severity. Mild (n=118) defined New York Heart Association (NYHA) class II Kansas City Cardiomyopathy Questionnaire...
Mutations in the lamin A/C gene are variably phenotypically expressed; however, it is unclear whether circulating cardiac biomarkers helpful detection and risk assessment of cardiolaminopathies. We sought to assess (1) clinical characteristics including serum biomarkers: high sensitivity troponin T (hsTnT) N-terminal prohormone brain natriuretic peptide (NT-proBNP) clinically stable cardiolaminopathy patients, (2) outcome among pathogenic/likely pathogenic (LMNA) mutation carriers. Our...
Background: An increasing number of patients is referred for orthotopic heart transplantation (OHT) after previous implantable cardioverter-defibrillator (ICD) or cardiac resynchronisation therapy (CRT) device implantation. Aim: To assess the rate unsuccessful lead extractions during OHT and propose an appropriate management algorithm. Methods: The study population included 73 consecutive who underwent in our hospital between January 2009 December 2011. Results: In group, 36 (49.3%)...